Navigation Links
Halozyme Therapeutics to Present at Upcoming Financial Conferences
Date:9/1/2011

SAN DIEGO, Sept. 1, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that management will be presenting at two upcoming financial conferences, the William Blair Life Sciences Conference in New York and the Stifel Nicolaus Healthcare Conference in Boston.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The William Blair Life Sciences Conference presentation is scheduled for Wednesday, September 7 at 11:30 a.m. EDT (8:30 a.m. PDT).

The Stifel Nicolaus Healthcare Conference is scheduled for Thursday, September 8 at 8:35 a.m. EDT (5:35 a.m. PDT).

To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. A replay will be available for 90 days after the event.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter, ViroPharma and Intrexon to apply Enhanze technology to therapeutic biologics including Herceptin®, MabThera®, immunoglobulin, Cinryze® and recombinant human alpha 1-antitrypsin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Halozyme Contact  
Kurt Gustafson
Chief Financial Officer
(858) 704-8272
kgustafson@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17
2. Halozymes Ultrafast Insulin Demonstrates Reduced Variability of Insulin Absorption for Type 1 Diabetes Patients Using Insulin Pumps
3. Halozyme and Intrexon Announce Collaboration to Develop First Subcutaneous Recombinant Alpha 1-Antitrypsin Replacement Therapy
4. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
5. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
6. Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12
7. Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6
8. Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
9. Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11
10. Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
11. Halozyme Therapeutics Realigns Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb. 22, 2017 Henry ... an exclusive distribution agreement with Rijuven, which develops ... diagnostic device to medical practitioners. ... electrocardiogram (ECG) and heart sound signals, transmits real-time ... and offers cloud-based analysis to help physicians provide ...
(Date:2/22/2017)... Calif. , Feb. 22, 2017  Bioness, Inc., ... therapies, today announced the first series of successful StimRouter ... at Radboud University Medical Center (Nijmegen, Netherlands ... ( Cork, Ireland ), and Kliniek Park ... the successful launch continuing, Bioness plans to further support ...
(Date:2/22/2017)... , Feb. 22, 2017 Oncternal Therapeutics, ... for both rare and common malignancies, today announced ... financing. The company intends to use the proceeds ... TK216, and to advance preclinical development of a ... Cirmtuzumab is a first-in-class anti-ROR1 monoclonal antibody being ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... ... newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This ... instant absorption from the mouth into the bloodstream. Far outpacing the ...
(Date:2/22/2017)... ... 22, 2017 , ... The Centers for Medicare & Medicaid ... in Delaware, New Jersey, Pennsylvania and West Virginia prepare for and participate in ... Act of 2015 (MACRA). , This technical assistance, authorized and funded under ...
(Date:2/22/2017)... NJ (PRWEB) , ... February 22, 2017 , ... ... healthcare communications company, launched a new media platform connecting healthcare technology professionals and ... will be followed by a quarterly publication starting on March 1, announced Michael ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pet obesity in the U.S. continued ... according to the Association for Pet Obesity Prevention (APOP). During the ninth annual survey, ... such as the benefits of corn and grains, value of raw and organic diets, ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... so many different solutions on the market, it is easy to start feeling ... Premier Locksmith offers a complimentary security consultation. , Home Security Hardware Choices, ...
Breaking Medicine News(10 mins):